Investigating the genetic relationship between depression symptoms and Alzheimer's disease in clinically diagnosed and proxy cases

Lachlan Gilchrist,Thomas P. Spargo,Rebecca E. Green,Jonathan R.I. Coleman,David M. Howard,Jackson G. Thorp,Brett Adey,Jodie Lord,Helena L. Davies,Jessica Mundy,Molly R. Davies,Christopher Hübel,Shannon Bristow,Sang Hyuck Lee,Henry Rogers,Charles Curtis,Gursharan Kalsi,Ryan Arathimos,Anne Corbett,Clive Ballard,Helen Brooker,Byron Creese,Dag Aarsland,Adam Hampshire,Latha Velayudhan,Thalia C. Eley,Gerome Breen,Alfredo Iacoangeli,Sulev Koks,Cathryn M. Lewis,Petroula Proitsi,Alzheimer's Disease Neuroimaging Initiative,AddNeuroMed,GERAD1 Consortium

DOI: https://doi.org/10.1101/2023.06.05.23290588

2023-06-08

MedRxiv

Abstract:Depression is a risk factor for the later development of Alzheimer's disease (AD), but evidence for their genetic relationship is mixed. Assessing depression symptom specific genetic associations may better clarify this relationship. Using data from the UK Biobank, the GLAD Study and PROTECT, we performed the largest genome-wide meta-analyses (GWAS) of the nine depression symptom items, plus their sum score, on the Patient Health Questionnaire (PHQ-9) (GWAS equivalent N: 224,535--308,421). We then assessed global and local genetic correlations and statistical colocalisation between depression/depression symptoms and AD across six AD GWAS with varying proportions of clinical and proxy (family history) case ascertainment. We assessed bi-directional causal associations using Mendelian randomisation (MR) and tested the predictive utility of depression/depression symptom polygenic risk scores (PRS) for AD case/control status in three clinical AD cohorts. Our GWAS meta-analyses identified 37 genomic risk loci across the ten depression symptom phenotypes. Of the 72 global genetic correlation tests conducted between depression/depression symptoms and AD, 20 were significant at pFDR [≤] 0.05. Only one significant genetic correlation was identified with AD GWAS containing clinical-only cases. Local genetic correlations were detected at 14 loci. Statistical colocalisation was not identified at these loci but was identified in the region of transmembrane protein 106B (TMEM106B) between multiple depression phenotypes and both clinical-only and clinical+proxy AD. MR and PRS analyses did not yield significant results after multiple testing correction. Our findings do not demonstrate a causal role of depression/depression symptoms on AD and suggest that previous evidence of genetic overlap between depression and AD may be driven by the inclusion of family-history-based proxy cases/controls. However, the identification of colocalisation at TMEM106B warrants further investigation.